A lieu le
23 novembre 2020
jusqu'au 24 novembre 2020
This international congress is jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign. It is part of the series of Industrial Symposia organized by MAbImprove since 2013, whose previous topics were: Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates, Targets for Mabs, and Harnessing the Immune System with Abs.
The AIS2020 is the ideal conference for scientists, industrials, physicians and policy makers to exchange about therapeutic antibodies.
The Scientific committee has set-up an exciting program around this year theme: "Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases", with keynote lectures, pitch talks around new creative projects, and industrial talks from big pharmaceutical companies.
The next frontier of Ab-based therapeutics for fighting diseases is the production and application of higher-order multispecific Abs or Ab-like molecules, as well as novel cytokine-based biologics or engineered artificial chimeric antigen receptors (CARs). Indeed multispecific Abs and next-generation immunocytokines provide promising platform for the development of novel therapeutic concepts that could facilitate the generation of safer, more effective pharmaceuticals. Re-directing immune cells with engineered CARs is an exciting approach for efficient adoptive cell therapy. AIS2020 will cover the multifaceted mechanisms induced by novel multimer derivatives, cytokine-based products and CARs in different pathophysiological situations. It will also focus on CMC developability (Chemistry Manufacturing Control) and the early clinical development.
The program will allow opportunities for networking, companies to showcase their new products and technologies as well as dedicated time for business partnering.